Forest Laboratories Inc., of New York, and Almirall SA, of Barcelona, Spain, said they recently received feedback from the FDA regarding the fixed-dose combination of aclidinium and formoterol and, while no new issues have arisen, will need further discussion with the agency to address questions related to chemistry, manufacturing and control.